Safety of moxifloxacin and voriconazole in corneal storage media on porcine corneal endothelial cells.
OBJECTIVE
The aim of this study was to evaluate the safety of moxifloxacin and voriconazole as a supplement in corneal storage media for porcine corneal endothelial cells.


METHODS
Twenty-eight eyes were divided into 4 groups. In the control group (the C group), corneal buttons were stored for 3 days in Optisol-GS. In the treatment group, the corneal buttons were preserved for 3 days in Optisol-GS mixed with 250 microg/mL moxifloxacin (M group), 100 microg/mL voriconazole (V group), and 250 microg/mL moxifloxacin plus 100 microg/mL voriconazole (MV group). We evaluated the samples via specular microscopy before and after 3 days of preservation. The mean changes of endothelial cell counts were compared among the 4 groups. Scanning electron microscopy was conducted after 3 days of preservation.


RESULTS
Before the preservation, the endothelial cell counts did not differ among the 4 groups (P > 0.05). After 3 days of preservation, the endothelial cell count in the MV group was the lowest among the 4 groups (P < 0.05). After 3 days of preservation, the rate of corneal endothelial cell loss in the M and V groups did not differ significantly from the control group (P > 0.05). The rate of endothelial cell loss in the MV group was significantly higher than that of the control group (P < 0.05). Scanning electron microscopy revealed a normal mosaic pattern for the C, V, and F groups, but hexagonality was not preserved in the MV group.


CONCLUSIONS
Preservation in Optisol-GS mixed with moxifloxacin (250 microg/mL) plus voriconazole (100 microg/mL) induced significant toxicity on the endothelial cells in porcine corneas, when compared with the control group.
Kim
Su-Young
SY
Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea , Seoul, Korea. cassiopeia@catholic.ac.kr
Yang
Jiwook
J
Lee
Young-Chun
YC
D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D001372:Aza Compounds / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D002809:Chondroitin Sulfates; D045424:Complex Mixtures; D003315:Cornea / Q000187:drug effects; D015925:Cryopreservation; D016895:Culture Media, Serum-Free; D003911:Dextrans; D004728:Endothelium, Corneal / Q000166:cytology / Q000187:drug effects*; D024841:Fluoroquinolones; D005839:Gentamicins; D000077266:Moxifloxacin; D019188:Organ Preservation Solutions; D011743:Pyrimidines / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D011804:Quinolines / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D013552:Swine; D014021:Tissue Preservation; D014230:Triazoles / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*; D065819:Voriconazole
D000890:Anti-Infective Agents; D001372:Aza Compounds; D045424:Complex Mixtures; D016895:Culture Media, Serum-Free; D003911:Dextrans; D024841:Fluoroquinolones; D005839:Gentamicins; D019188:Organ Preservation Solutions; D011743:Pyrimidines; D011804:Quinolines; D014230:Triazoles; D002809:Chondroitin Sulfates; C075736:Optisol; D065819:Voriconazole; D000077266:Moxifloxacin